High-glycolytic cancers and their interplay with the body's glucose demand and supply cycle

Medical Hypotheses

Volumn 76, Issue 2, 2011, Pages 157-165

  Mathews, Edward Henry ^a   Liebenberg, Leon ^a   Pelzer, Ruaan ^a  

^a NONE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLUCOSE; GLUTAMINE; LACTIC ACID;

ARTICLE; BYSTANDER EFFECT; CANCER CELL; CANCER CONTROL; CANCER THERAPY; CELL KILLING; CELL METABOLISM; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; GLYCOLYSIS; HEMODIAFILTRATION; HEMODIALYSIS; HUMAN; HYPOXIA; IN VIVO STUDY; INSULIN TREATMENT; LIFESTYLE MODIFICATION; LIPID OXIDATION; METASTASIS;

ANIMALS; ANOXIA; BLOOD GLUCOSE; BRAIN; CELL LINE, TUMOR; FATTY ACIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMINE; GLYCOLYSIS; HUMANS; IMMUNE SYSTEM; LACTATES; MODELS, BIOLOGICAL; NEOPLASMS; TREATMENT OUTCOME;

EID: 78651106477     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.09.006     Document Type: Article

References (121)

1. Bertout J.A., Patel S.A., Simon M.C. The impact of O2 availability on human cancer. Nat Rev Cancer (Hypoxia and Metabolism Collection) 2009, (November):34-42.
2. Kitano H. Cancer as a robust system: implications for anticancer therapy. Nat Rev Cancer 2004, 4:227-235.
3. Jones R.G., Thompson C.B. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 2009, 23:537-548.
4. Feron O. Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Rad Oncol 2009, 92:329-333.
5. Jain K.J. A new target for tumor therapy. New Eng J Med 2009, 360:2669-2671.
6. Mankoff D.A., et al. Blood flow metabolism mismatch: good for the tumor, bad for the patient. Clin Cancer Res 2009, 15:5294-5296.
7. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Sem Rad Oncol 2004, 14:198-206.
8. Gray L.H., et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiolog 1953, 26:638-648.
9. Brahimi-Horn M.C., Chiche J., Pouysségur J. Hypoxia and cancer. J Mol Med 2007, 85:1301-1307.
10. Helmlinger G. Interstitial pH and PO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 1997, 3:177-182.
11. Kroemer G., Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008, 13:472-482.
12. Moreno-Sánchez R., Rodríguez-Enríquez S., Marin-Hernández A., Saavedra E. Energy metabolism in tumor cells. FEBS J 2007, 274:1393-1418.
13. Seyfried T.N., Mukherjee P. Targeting energy metabolism in brain cancer: review and hypothesis. Nutr Metab 2005, 2:30.
14. Seyfried T.N., Shelton L.M. Cancer as a metabolic disease. Nutr Metab 2010, 7:7.
15. Komar G., et al. Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin Cancer Res 2009, 15:5511-5517.
16. Wheatley D.N., Campbell E., Lai P.B.S., Cheng P.N.M. A rational approach to the systemic treatment of cancer involving medium-term depletion of arginine. Gene Ther Mol Biol 2005, 9:33-40.
17. Zirngibl H., Husemann B., Hermanek P. Intraoperative spillage of tumor cells in surgery for rectal cancer. Dis Colon Rectum 2005, 33:610-614.
18. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed' and 'soil' hypothesis revisited. Nat Rev Cancer 2003, 3:1-6.
19. Vousden K.H., Ryan K.M. P53 and metabolism. Nat Rev Cancer 2009, 9:691-700.
20. Lee J.L., et al. Glucose deprivation-induced cytoxicity and alterations in mitogen-activated protein kinase activation are mediated by oxidative stress in multidrug-resistant human breast carcinoma cells. J Biol Chem 1997, 273:5294-5299.
21. Guppy M., Leedman P., Zu X., Russell V. Contribution by different fuels and metabolic pathways to the total ATP turnover of proliferating MCF-7 breast cancer cells. Biochem J 2002, 364:309-315.
22. Mazurek S., Michel A., Eigenbrodt E. Effect of extracellular AMP on cell proliferation and metabolism of breast cancer cell lines with high and low glycolytic rates. J Biol Chem 1997, 57:159-164.
23. Zu X.L., Guppy M. Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun 2004, 313:459-465.
24. Walenta S., et al. High lactate levels predict likelihood of metastasis, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res 2000, 60:916-921.
25. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
26. DeBerardinis R.J., Lum J.J., Hatzivassiliou G., Thompson C.B. The biology of cancer: metabolic reprogramming that fuels growth and proliferation. Cell Metab 2000, 7:11-20.
27. Kim J.W., Dang C.V. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006, 66:8927-8930.
28. Warburg O. On the origin of cancer cells. Science 1956, 23:309-314.
29. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
30. Menendez J.A., Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007, 7:763-777.
31. Chi V.D., Semenza G.L. Oncogenic alterations of metabolism. TIBS 1999, 24:68-72.
32. Gatenby R.A., Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer 2004, 4:891-899.
33. Dang C.V., Semenza G.L. Oncogenic alterations of metabolism. TIBS 1999, 24:68-72.
34. Shaw R.J. Glucose metabolism and cancer. Curr Opin Cell Biol 2006, 18:598-608.
35. Garber K. Energy deregulation: licensing tumors to grow. Science 2006, 312:1158-1159.
36. Murray RK, Granner DK, Rodwell VW, editors. Harper's illustrated biochemistry. 27th ed. New York: McGraw-Hill; 2006.
37. Guppy M., Geriner E., Brand K. The role of the Crabtree effect and an endogenous fuel in the energy metabolism of resting and proliferating thymocytes. Eur J Biochem 1993, 212:95-99.
38. Dietzen D.J., Davis E.J. Oxidation of pyruvate, malate, citrate, and cytosolic reducing equivalents by AS-30D hepatoma mitochondria. Arch Biochem Biophys 1993, 305:91-102.
39. Rodríguez-Enríquez S., Torres-Márquez M.E., Moreno-Sánchez R. Substrate oxidation and ATP supply in AS-30D hepatoma cells. Arch Biochem Biophys 2000, 375:21-30.
40. Lichtor T., Dohrmann G.J. Oxidative metabolism and glycolysis in benign brain tumors. J Neurosurg 1987, 67:336-340.
41. Capuano F., et al. Oxidative phosphorylation and F0F1 ATP synthase activity of human hepatocellular carcinoma. Biochem Mol Biol Int 1996, 38:1013-1022.
42. Marin-Hernandez A., et al. Determining and understanding the control of glycolysis in fast-growth tumor cells. Flux control by an over-expressed but strongly product-inhibited hexokinase. FEBS J 2006, 273:1975-1988.
43. Nakashima R.A., Paggi M.G., Scott L.J., Pedersen P.L. Purification and characterization of bindable form of mitochondrial bound hexokinase from the highly glycolytic AS-30D rat hepatoma cell line. Cancer Res 1988, 48:913-919.
44. Balinsky D., Platz C.E., Lewis J.W. Enzyme activities in normal, dysplastic, and cancerous human breast tissues. J Natl Cancer Inst 1984, 72:217-224.
45. Briscoe D.A., Fiskum G., Holleran A.L., Kelleher J.K. Acetoacetate metabolism in AS-30D hepatoma cells. Mol Cell Biochem 1994, 136:131-137.
46. Molina M., et al. Glutamine transport by vesicles isolated from tumour-cell mitochondrial membrane. Biochem J 1995, 308:629-633.
47. Tennant D.A., Durán R.V., Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 2010, 10:267-277.
48. Kaadige M.R., Looper R.E., Kamalanaadhan S., Ayer D.E. Glutamine-dependent anapleurosis dictates glucose uptake and cell growth by regulating MondoA transcriptional activity. PNAS 2009, 106:14878-14883.
49. DeBerardinis R.J., Cheng T. Q's next" the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2010, 29:313-324.
50. Young C.D., Anderson S.M. Sugar and fat-that's where it's at: metabolic changes in tumors. Breast Cancer Res 2008, 10:9.
51. Fantin V.R., St-Pierre J., Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology and tumour maintenance. Cancer Cell 2006, 9:425-434.
52. Ganapathy V., Thangaraju M., Prasad P.D. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 2009, 121:29-40.
53. Sonveaux P., et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 2008, 118:3930-3942.
54. Howell A., Chapman M., Harvie M. Energy restriction for breast cancer prevention. Cancer prevention 2009, vol. II. Springer-Verlag, Berlin.
55. Martin D.S., Spriggs D., Kroutcher J.A. A concomitant ATP-depleting strategy markedly enhances anticancer activity. Apoptosis 2001, 6:125-131.
56. Simons A.L., Matson D.M., Dornfeld K., Spitz D.R. Glucose deprivation-induced metabolic oxidative stress and cancer therapy. J Cancer Res Ther 2009, 1:S2-S6.
57. Jelluma N., et al. Glucose withdrawal induces oxidative stress followed by apoptosis in glioblastoma but not in normal human astrocytes. Mol Cancer Res 2006, 4:319-330.
58. Lin X., et al. 2-Deoxy-d-glucose-induced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism. Cancer Res 2003, 63:3413-3417.
59. Geschwind J.F., Georgiades C.S., Ko Y.H., Pedersen P.L. Novel therapy for liver cancer: direct intra-arterial injection of a potent inhibitor of ATP production. Cancer Res 2002, 62:3909-3913.
60. Aykin-Burns N., Ahmad I.M., Zhu Y., Oberley L.W., Spitz D.R. Increased levels of superoxide and hydrogen peroxide mediate the differential susceptibility of cancer cells vs. normal cells to glucose deprivation. Biochem J 2009, 418:29-37.
61. Ko Y.H., et al. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 2004, 3:269-275.
62. Wise D.R., et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. PNAS 2008, 105:18782-18787.
63. Yuneva M., Zamboni N., Oefner P., Sachidanandam R., Lazebnik Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol 2007, 178:93-105.
64. Peters A., et al. The selfish brain: competition for energy resources. Neurosci Biobehav Rev 2004, 28:143-180.
65. Shankar L.K., et al. Consensus recommendation for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. J Nucl Med 2006, 47:1059-1066.
66. Huang S.-C. Anatomy of SUV. Nucl Med Biol 2000, 27:643-646.
67. Zasadny K.R., Wahl R.L. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-d-glucose: variations with body weight and a method for correction. Radiology 1993, 189:847-850.
68. Kosaka N., et al. 18F-FDG PET of common enhancing malignant brain tumours. AJR 2008, 190:W365-W369.
69. Escobar G.A., et al. Severe paraneoplastic hypoglycemia in a patient with a gastrointestinal stromal tumor with an exon 9 mutation: a case report. BMC Cancer 2007, 7:6.
70. Pink D., et al. Severe hypoglycemia caused by paraneoplastic production of IGF-II in patients with advanced gastrointestinal stromal tumors: a report for two cases. J Clin Oncol 2005, 2:6809-6811.
71. Finora D.V.M.K. Common paraneoplastic syndromes. Med Oncol 2003, 18:123-126.
72. Nauck M.A., et al. Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastizing large-cell carcinoma of the lung. J Clin Endocrin Metab 2007, 92:1600-1605.
73. Delbeke D., et al. Evaluation of benign and malignant hepatic lesions with positron emission tomography. Arch Surg 2009, 133:510-516.
74. Vaupel P., Kallinowski F., Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989, 49:6449-6465.
75. Chin B.B., Green E.D., Turkington T.G., Hawk T.C., Coleman R.E. Increasing uptake time in FDG-PET: standardized uptake values in normal tissues at 1 versus 3h. Mol Imaging Biol 2008, 11:118-122.
76. Lowrie O.H. Diversity of metabolic patterns in human brain tumors: enzymes of energy metabolism and related metabolites and cofactors. J Neurochem 1983, 41:994-1010.
77. Dastidar S.G., Sharma S.K. Activities of glycolytic enzymes in rapidly proliferating and differentiated C6 glioma cells. Exp Cell Biol 1989, 57:159-164.
78. Wong C.O., et al. Correlating metabolic and anatomic responses of primary lung cancers to radiotherapy by combined F-18 FDG PET-CT imaging. Rad Oncol 2007, 2.
79. Weber W.A., et al. Positron emission tomography in non-small cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003, 21:2651-2657.
80. Tateishi U., et al. Bone metastasis is patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology 2008, 247:189-196.
81. Kallinowski F., Schlenger K.H., Kloes M., Stohrer M., Vaupel P. Tumor blood flow: the principal modulator of oxidative and glycolytic metabolism, and of the metabolic micromilieu of human tumor xenografts in vivo. Int J Cancer 1989, 44:266-272.
82. Kenny L.M., et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by 18F Fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res 2005, 65:10104-10112.
83. Mankoff D.A., Bellon J.R. Positron emission tomography imaging of cancer: glucose metabolism and beyond. Semin Radiat Oncol 2001, 11:16-27.
84. Byström P., et al. Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-deoxy-d-glucose positron emission tomography in patients with advanced colorectal cancer. Ann Oncol 2009, 20:1057-1061.
85. Cascini G.L., et al. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med 2007, 47:1241-1248.
86. Schiepers C., Hoh C.K. Positron emission tomography as a diagnostic tool in oncology. Eur Radiol 1998, 8:1481-1494.
87. Fanciulli M., et al. Glucose metabolism in adriamycin-sensitive and -resistant LoVo human colon carcinoma cells. Oncol Res 1993, 5:357-362.
88. Jadvar H., Ye W., Groshen S., Conti P.S. [F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland. Ann Nucl Med 2008, 22:787-793.
89. Wang Y., Chiu E., Rosenberg J., Gambhir S.S. Standardized uptake value atlas: characterization of physiological 2-deoxy-2-[18F] fluoro-d-glucose uptake in normal tissue. Mol Imaging Biol 2007, 9:83-90.
90. Van Loon L.J.C., Greenhaff P.L., Constantin-Teodosiu D., Saris W.H.M., Wagenmakers A.J.M. The effects of increasing exercise intensity on muscle fuel utilisation in humans. J Physiol 2001, 536:295-304.
91. Casazza J.P., Felver M.E., Veech R.L. The metabolism of acetone in rat. J Biol Chem 1984, 259:231-236.
92. Siegel GJ, Agranoff BW, Fisher SK, Albers RW, Uhler MD, editors. Basic neurochemistry: molecular, cellular and medical aspects. 6th ed. Philadelphia: Lippincott-Raven Publishers; 1998.
93. Cryer P.E. Hypoglycemia, functional brain failure, and brain death. J Clin Invest 2007, 117:868-870.
94. Auer R.N. Hypoglycemic brain damage. Foren Sci Int 2004, 146:105-110.
95. Choi I.-Y., Lee S.-P., Kim S.-G., Gruetter R. In vivo measurements of brain glucose transport using the reversible Michaelis-Menten model and simultaneous measurements of cerebral blood flow changes during hypoglycemia. J Cereb Blood Flow Metab 2001, 21:653-663.
96. Gruetter R., Ugurbil K., Seaquist E.R. Steady-state cerebral glucose concentrations and transport in the human brain. J Neurochem 1998, 70:397-408.
97. Poitry-Yamate C., Lei H.X., Gruetter R. The rate-limiting step for glucose transport into the hypothalamus is across the blood-hypothalamus interface. J Neurochem 2009, 109(Suppl.):38-45.
98. Lippincott's illustrated reviews: biochemistry 2008, Lippincott Williams and Wilkins, Baltimore, MD. P.C. Champe, R.A. Harvey (Eds.).
99. Öz G., et al. Human brain glycogen metabolism during and after hypoglycemia. Diabetes 2009, 58:1978-1985.
100. Öz G., et al. Human brain glycogen content and metabolism: implications on its role in brain energy metabolism. Am J Physiol Endocrinol Metab 2007, 292:E946-E951.
101. Cahill G.F., et al. Hormone-fuel interrelationships during fasting. J Clin Invest 1966, 45:1751-1769.
102. Patel A.B., et al. Glutamatergic neurotransmission and neuronal glucose oxidation are coupled during intense neuronal activation. J Cereb Blood Flow 2004, 24:972-985.
103. Mantis J.G., Centeno N.A., Todorova M.T., McGowan R., Seyfried T.N. Management of multifactorial idiopathic epilepsy in EL mice with caloric restriction and the ketogenic diet: role of glucose and ketone bodies. Nutr Metab 2004, 1:11.
104. Pan J.W., Rothman D.L., Behar K.L., Stein D.T., Hetherington H.P. Human brain β-hydroxybutyrate and lactate increase in fasting-induced ketosis. Cereb Blood Flow Metab 2000, 20:1502-1507.
105. Mathews EH. An installation and method for the treatment of cancer. International PCT/IB2008/055112, 2007.
106. Gatenby R.A. A change of strategy in the war on cancer. Nature 2009, 459:508-509.
107. Ayre S.G., Perez Garcia, Bellon D., Perez Garcia D. IPT: a new concept in the management of chronic degenerative disease. Med Hypoth 1986, 20:199-210.
108. Pollak M. Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer 2009, 8:915-928.
109. Evans J.M., Donnely L.A., Emslie-Smith A.M., Alessi D.R., Morris A.D. Metformin and reduced risk of cancer in diabetes patients. BMJ 2005, 330:1304-1305.
110. Ilvesmaki V., et al. Insulin-like growth factors (IGFs) and their receptors in adrenal tumours: high IGF-II expression in functional adrenocortical carcinomas. J Clin Endocrin Metab 1993, 77:852-858.
111. Gerstein H.C. Does insulin therapy promote, reduce, or have a neutral effect on cancers?. JAMA 2010, 303:446-447.
112. Hildebrand G.E., Mathews E.H. Using simulation to study the effect of stress on blood glucose levels. Diabetes 2004, 53:A516.
113. Eggermont A.M.M., De Wilt J.H.W., Ten Hagen T.L.M. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003, 4:429-437.
114. Bonvalot S., et al. Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoids-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient. Ann Surg Oncol 2009, 16:3350-3357.
115. Grünhagen D., et al. Isolated limb perfusion with tumor necrosis factor and melphalan prevents amputation in patients with multiple sarcomas in arm or leg. Ann Surg Oncol 2005, 12:1-7.
116. Grover A., Alexander H.R. The past decade of experience with isolated hepatic perfusion. Oncology 2004, 9:653-664.
117. Daugirdas J.T., Blake P.G., Todd S.I. Handbook of dialysis 2001, Lippincott, Williams and Wilkins, Philadelphia. 3rd ed.
118. Bosch J.P., Stein J.H. Hemodialysis, high-efficiency treatments 1993, Churchill Livingstone Inc., New York.
119. Levy J., Brown E., Daley C., Lawrence A. Oxford handbook of dialysis 2009, Oxford University Press. 3rd ed.
120. Cahill G.F. Fuel metabolism in starvation. Annu Rev Nutr 2006, 26:1-22.
121. Alba E., et al. Transcatheter arterial chemoembolization in patients with hepatocellular carcinoma on the waiting list for orthotopic liver transplantation. AJR 2007, 190:1341-1348.